FDA Clears Full-Wavelength Capability for Lasermach Laser System

Wingderm announced that its Lasermach laser system has received expanded clearance from the US Food and Drug Administration (FDA), enabling use across all 3 wavelengths—755 nm, 808 nm, and 1064 nm. The update includes clearance for a mixed-wavelength handpiece combining all 3 wavelengths, as well as individual single-wavelength configurations.

According to the company, the mixed-wavelength handpiece is indicated for temporary hair reduction and the treatment of benign vascular and vascular-dependent lesions. Single-wavelength handpieces are cleared for hair removal and permanent hair reduction across all Fitzpatrick skin types (I–VI), broadening the system’s clinical applicability compared with earlier configurations.

The expanded clearance allows clinicians to address a wider range of hair types and skin tones using a single platform. This may reduce the need for multiple devices in aesthetic practices and streamline workflow in high-volume settings such as medical spas.

Wingderm plans to present the Lasermach system at the American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 27–29 in Denver, Colorado. Attendees will be able to review the device’s capabilities and clinical applications at the company’s exhibit.